{"id":228092,"date":"2025-07-15T11:50:50","date_gmt":"2025-07-15T08:50:50","guid":{"rendered":"https:\/\/www.ghafla.co.ke\/ke\/?p=228092"},"modified":"2025-07-15T11:50:50","modified_gmt":"2025-07-15T08:50:50","slug":"beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection","status":"publish","type":"post","link":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/","title":{"rendered":"Beyond Daily Pills- WHO Backs New Long-Acting HIV Prevention Injection"},"content":{"rendered":"<p><span class=\"citation-33\">The <\/span><span class=\"citation-33\">World Health Organization (WHO)<\/span><span class=\"citation-33\"> has released groundbreaking new guidelines recommending the use of <\/span><span class=\"citation-33\">injectable lenacapavir (LEN) twice a year<\/span><span class=\"citation-33 citation-end-33\"> as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention.<\/span> This recommendation marks a landmark policy action poised to significantly reshape the global HIV response.<\/p>\n<p><span class=\"citation-32\">Lenacapavir, recognized as the <\/span><span class=\"citation-32\">first twice-yearly injectable PrEP product<\/span><span class=\"citation-32 citation-end-32\">, offers a highly effective and long-acting alternative to daily oral pills and other shorter-acting prevention methods.<\/span> <span class=\"citation-31 citation-end-31\">With just two doses per year, LEN represents a transformative step forward in protecting individuals at risk of HIV, particularly those who encounter difficulties with daily medication adherence, face significant stigma, or have limited access to consistent health care.<\/span><\/p>\n<p><span class=\"citation-30\">Speaking at the 13th International AIDS Society Conference (IAS 2025) on HIV Science in Kigali, Rwanda, where the guidelines were issued, WHO Director-General <\/span><span class=\"citation-30\">Dr. Tedros Adhanom Ghebreyesus<\/span><span class=\"citation-30 citation-end-30\"> emphasized the importance of this development.<\/span> <span class=\"citation-29 citation-end-29\">He stated that while an HIV vaccine remains elusive, lenacapavir stands as &#8220;the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk.&#8221;<\/span><\/p>\n<p>Dr. Tedros further articulated WHO&#8217;s commitment:<\/p>\n<blockquote><p>&#8220;The launch of WHO\u2019s new guidelines, alongside the FDA\u2019s recent approval, marks a critical step forward in expanding access to this powerful tool. WHO is committed to working with countries and partners to ensure this innovation reaches communities as quickly and safely as possible.\u201d<\/p><\/blockquote>\n<p>The issuance of these new guidelines comes at a critical juncture, as global HIV prevention efforts have shown signs of stagnation, with an alarming 1.3 million new HIV infections occurring in 2024. <span class=\"citation-28 citation-end-28\">This impact is disproportionately felt among key and priority populations, including sex workers, men who have sex with men, transgender people, people who inject drugs, people in prisons, and children and adolescents.<\/span> <span class=\"citation-27 citation-end-27\">WHO\u2019s recommendation on LEN signals a decisive move to expand and diversify HIV prevention strategies, providing individuals with more practical options to take control over their health with choices that better integrate into their daily lives.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The World Health Organization (WHO) has released groundbreaking new guidelines recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention. This recommendation marks a landmark policy action poised to significantly reshape the global HIV response. Lenacapavir, recognized as the first twice-yearly injectable PrEP product, offers [&hellip;]<\/p>\n","protected":false},"author":6073,"featured_media":228095,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[310],"tags":[139971],"class_list":["post-228092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-entertainment","tag-who-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Beyond Daily Pills- WHO Backs New Long-Acting HIV Prevention Injection - Ghafla! Kenya<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beyond Daily Pills- WHO Backs New Long-Acting HIV Prevention Injection - Ghafla! Kenya\" \/>\n<meta property=\"og:description\" content=\"The World Health Organization (WHO) has released groundbreaking new guidelines recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention. This recommendation marks a landmark policy action poised to significantly reshape the global HIV response. Lenacapavir, recognized as the first twice-yearly injectable PrEP product, offers [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/\" \/>\n<meta property=\"og:site_name\" content=\"Ghafla! Kenya\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ghaflakenya\" \/>\n<meta property=\"article:author\" content=\"https:\/\/web.facebook.com\/dennis.omwange.98\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T08:50:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2025\/07\/WHO.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"614\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dennis Elnino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@GhaflaKenya\" \/>\n<meta name=\"twitter:site\" content=\"@GhaflaKenya\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Elnino\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/\"},\"author\":{\"name\":\"Dennis Elnino\",\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/#\/schema\/person\/04ece91a7b4da54f20f94b28041f5709\"},\"headline\":\"Beyond Daily Pills- WHO Backs New Long-Acting HIV Prevention Injection\",\"datePublished\":\"2025-07-15T08:50:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/\"},\"wordCount\":334,\"publisher\":{\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2025\/07\/WHO.jpg\",\"keywords\":[\"WHO News\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.ghafla.co.ke\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/\",\"url\":\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/\",\"name\":\"Beyond Daily Pills- WHO Backs New Long-Acting HIV Prevention Injection - Ghafla! Kenya\",\"isPartOf\":{\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2025\/07\/WHO.jpg\",\"datePublished\":\"2025-07-15T08:50:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#primaryimage\",\"url\":\"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2025\/07\/WHO.jpg\",\"contentUrl\":\"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2025\/07\/WHO.jpg\",\"width\":1024,\"height\":614,\"caption\":\"This photograph taken on July 3, 2020, shows a sign of the World Health Organization (WHO) at their headquarters in Geneva, amidst the COVID-19 outbreak, caused by the novel coronavirus. (Photo by Fabrice COFFRINI \/ AFP) (Photo by FABRICE COFFRINI\/AFP via Getty Images)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ghafla.co.ke\/ke\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beyond Daily Pills- WHO Backs New Long-Acting HIV Prevention Injection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/#website\",\"url\":\"https:\/\/www.ghafla.co.ke\/ke\/\",\"name\":\"Ghafla! Kenya\",\"description\":\"Get The Latest Kenyan Entertainment News\",\"publisher\":{\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ghafla.co.ke\/ke\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/#organization\",\"name\":\"Ghafla! Kenya\",\"url\":\"https:\/\/www.ghafla.co.ke\/ke\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2023\/03\/Screen-Shot-2016-10-20-at-12.38.43.png\",\"contentUrl\":\"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2023\/03\/Screen-Shot-2016-10-20-at-12.38.43.png\",\"width\":600,\"height\":309,\"caption\":\"Ghafla! Kenya\"},\"image\":{\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ghaflakenya\",\"https:\/\/x.com\/GhaflaKenya\",\"https:\/\/www.instagram.com\/ghaflakenya\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/#\/schema\/person\/04ece91a7b4da54f20f94b28041f5709\",\"name\":\"Dennis Elnino\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ghafla.co.ke\/ke\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c803988b6503d0e1f521ed50b0437021a7760d2fdaf45e4977658d09dfba927c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c803988b6503d0e1f521ed50b0437021a7760d2fdaf45e4977658d09dfba927c?s=96&d=mm&r=g\",\"caption\":\"Dennis Elnino\"},\"description\":\"Content Developer Email: denniselnino31@gmail.com\",\"sameAs\":[\"https:\/\/web.facebook.com\/dennis.omwange.98\/\",\"https:\/\/www.instagram.com\/denniselnino\/\"],\"url\":\"https:\/\/www.ghafla.co.ke\/ke\/author\/denniselnino\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Beyond Daily Pills- WHO Backs New Long-Acting HIV Prevention Injection - Ghafla! Kenya","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/","og_locale":"en_US","og_type":"article","og_title":"Beyond Daily Pills- WHO Backs New Long-Acting HIV Prevention Injection - Ghafla! Kenya","og_description":"The World Health Organization (WHO) has released groundbreaking new guidelines recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention. This recommendation marks a landmark policy action poised to significantly reshape the global HIV response. Lenacapavir, recognized as the first twice-yearly injectable PrEP product, offers [&hellip;]","og_url":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/","og_site_name":"Ghafla! Kenya","article_publisher":"https:\/\/www.facebook.com\/ghaflakenya","article_author":"https:\/\/web.facebook.com\/dennis.omwange.98\/","article_published_time":"2025-07-15T08:50:50+00:00","og_image":[{"width":1024,"height":614,"url":"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2025\/07\/WHO.jpg","type":"image\/jpeg"}],"author":"Dennis Elnino","twitter_card":"summary_large_image","twitter_creator":"@GhaflaKenya","twitter_site":"@GhaflaKenya","twitter_misc":{"Written by":"Dennis Elnino","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#article","isPartOf":{"@id":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/"},"author":{"name":"Dennis Elnino","@id":"https:\/\/www.ghafla.co.ke\/ke\/#\/schema\/person\/04ece91a7b4da54f20f94b28041f5709"},"headline":"Beyond Daily Pills- WHO Backs New Long-Acting HIV Prevention Injection","datePublished":"2025-07-15T08:50:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/"},"wordCount":334,"publisher":{"@id":"https:\/\/www.ghafla.co.ke\/ke\/#organization"},"image":{"@id":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2025\/07\/WHO.jpg","keywords":["WHO News"],"articleSection":["News"],"inLanguage":"en-US","copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/www.ghafla.co.ke\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/","url":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/","name":"Beyond Daily Pills- WHO Backs New Long-Acting HIV Prevention Injection - Ghafla! Kenya","isPartOf":{"@id":"https:\/\/www.ghafla.co.ke\/ke\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#primaryimage"},"image":{"@id":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2025\/07\/WHO.jpg","datePublished":"2025-07-15T08:50:50+00:00","breadcrumb":{"@id":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#primaryimage","url":"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2025\/07\/WHO.jpg","contentUrl":"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2025\/07\/WHO.jpg","width":1024,"height":614,"caption":"This photograph taken on July 3, 2020, shows a sign of the World Health Organization (WHO) at their headquarters in Geneva, amidst the COVID-19 outbreak, caused by the novel coronavirus. (Photo by Fabrice COFFRINI \/ AFP) (Photo by FABRICE COFFRINI\/AFP via Getty Images)"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ghafla.co.ke\/ke\/beyond-daily-pills-who-backs-new-long-acting-hiv-prevention-injection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ghafla.co.ke\/ke\/"},{"@type":"ListItem","position":2,"name":"Beyond Daily Pills- WHO Backs New Long-Acting HIV Prevention Injection"}]},{"@type":"WebSite","@id":"https:\/\/www.ghafla.co.ke\/ke\/#website","url":"https:\/\/www.ghafla.co.ke\/ke\/","name":"Ghafla! Kenya","description":"Get The Latest Kenyan Entertainment News","publisher":{"@id":"https:\/\/www.ghafla.co.ke\/ke\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ghafla.co.ke\/ke\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ghafla.co.ke\/ke\/#organization","name":"Ghafla! Kenya","url":"https:\/\/www.ghafla.co.ke\/ke\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ghafla.co.ke\/ke\/#\/schema\/logo\/image\/","url":"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2023\/03\/Screen-Shot-2016-10-20-at-12.38.43.png","contentUrl":"https:\/\/www.ghafla.co.ke\/ke\/wp-content\/uploads\/sites\/4\/2023\/03\/Screen-Shot-2016-10-20-at-12.38.43.png","width":600,"height":309,"caption":"Ghafla! Kenya"},"image":{"@id":"https:\/\/www.ghafla.co.ke\/ke\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ghaflakenya","https:\/\/x.com\/GhaflaKenya","https:\/\/www.instagram.com\/ghaflakenya\/"]},{"@type":"Person","@id":"https:\/\/www.ghafla.co.ke\/ke\/#\/schema\/person\/04ece91a7b4da54f20f94b28041f5709","name":"Dennis Elnino","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ghafla.co.ke\/ke\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c803988b6503d0e1f521ed50b0437021a7760d2fdaf45e4977658d09dfba927c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c803988b6503d0e1f521ed50b0437021a7760d2fdaf45e4977658d09dfba927c?s=96&d=mm&r=g","caption":"Dennis Elnino"},"description":"Content Developer Email: denniselnino31@gmail.com","sameAs":["https:\/\/web.facebook.com\/dennis.omwange.98\/","https:\/\/www.instagram.com\/denniselnino\/"],"url":"https:\/\/www.ghafla.co.ke\/ke\/author\/denniselnino\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ghafla.co.ke\/ke\/wp-json\/wp\/v2\/posts\/228092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ghafla.co.ke\/ke\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ghafla.co.ke\/ke\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ghafla.co.ke\/ke\/wp-json\/wp\/v2\/users\/6073"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ghafla.co.ke\/ke\/wp-json\/wp\/v2\/comments?post=228092"}],"version-history":[{"count":1,"href":"https:\/\/www.ghafla.co.ke\/ke\/wp-json\/wp\/v2\/posts\/228092\/revisions"}],"predecessor-version":[{"id":228096,"href":"https:\/\/www.ghafla.co.ke\/ke\/wp-json\/wp\/v2\/posts\/228092\/revisions\/228096"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ghafla.co.ke\/ke\/wp-json\/wp\/v2\/media\/228095"}],"wp:attachment":[{"href":"https:\/\/www.ghafla.co.ke\/ke\/wp-json\/wp\/v2\/media?parent=228092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ghafla.co.ke\/ke\/wp-json\/wp\/v2\/categories?post=228092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ghafla.co.ke\/ke\/wp-json\/wp\/v2\/tags?post=228092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}